Harrow (HROW) Form 3: 33,000‑Share Option at $48.18

Harrow, Inc. director/officer Francis William Mullery Jr. reported an initial beneficial ownership filing dated 10/06/2025.

Rhea-AI Filing Summary

Harrow, Inc. director/officer Francis William Mullery Jr. reported an initial beneficial ownership filing dated 10/06/2025. The filing discloses a stock option for 33,000 shares of common stock with an exercise price of $48.18. The option vests 25% after one year and the remainder in equal quarterly installments over the next three years, becoming fully vested and exercisable on 09/30/2029. The form was signed on 10/10/2025.

Positive

• Time‑based vesting (25% after one year, then quarterly) encourages retention through 09/30/2029
• Clear exercise price disclosed at $48.18, enabling transparent valuation of the option

Negative

• None.

Insights

Corporate Governance Analyst

Officer received a time‑based option for 33,000 shares at $48.18, standard vesting.

This grant aligns management incentives with shareholder value by tying potential gain to future stock performance through a multi‑year vesting schedule. The initial 25% cliff followed by quarterly vesting over three years is a common approach to retain executives and link pay to tenure.

The main dependencies are future stock price and continued service until full vesting on 09/30/2029. Investors should note the $48.18 exercise price relative to current market levels when assessing potential dilution or incentive alignment within the next 2025–2029 timeframe.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mullery Francis William Jr

Role CEO, ImprimisRx

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 33,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option shall vest according to the following schedule: 25% of the shares shall vest at the one-year anniversary of the date of grant, and the remaining shares shall vest over the next three years in 12 equal quarterly installments until fully vested and exercisable on September 30, 2029.

FAQ

What did Francis Mullery Jr. report on the Form 3 for HROW?

He reported a stock option for 33,000 shares with an exercise price of $48.18 and a vesting schedule that makes it fully exercisable on 09/30/2029.

When was the Form 3 event dated for HROW?

The event requiring the statement is dated 10/06/2025, with the form signed on 10/10/2025.

What is the vesting schedule for the option disclosed by HROW Form 3?

Vesting is 25% at the one‑year anniversary of the grant, then quarterly over the next three years until fully vested on 09/30/2029.

How many shares underlie the derivative security reported on HROW Form 3?

The derivative security underlies 33,000 shares of common stock.

What is the significance of the exercise price on the Form 3 for HROW?

The exercise price is $48.18, which determines the cost to convert the option into common shares and is a key input for option valuation and potential dilution analysis.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/10/2025 - 06:22 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Mullery Francis William Jr

(Last) (First) (Middle)

C/O HARROW, INC.

1A BURTON HILLS SUITE 200

(Street)

NASHVILLE TN 37215

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/06/2025

3. Issuer Name and Ticker or Trading Symbol
HARROW, INC. [ HROW ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, ImprimisRx

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)(1)	(1)	09/30/2035	Common stock	33,000	$48.18	D

Explanation of Responses:

1. The shares subject to the option shall vest according to the following schedule: 25% of the shares shall vest at the one-year anniversary of the date of grant, and the remaining shares shall vest over the next three years in 12 equal quarterly installments until fully vested and exercisable on September 30, 2029.

Remarks:

Exhibit 24 - POWER OF ATTORNEY

	/s/ Andrew R. Boll as Attorney in Fact for Francis Mullery	10/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.